I-Mab (天境生物) Lock-Up Expiry: A Differentiated Immunotherapy Player Worth Reverse Inquiry
I-Mab was listed in the US on Jan 17th and returned 96% since listing. I-Mab has a highly differentiated two segments of products, including...
433 Views
Dada Nexus (达达集团) IPO Trading - Larger Deal Size with Decent Potential Upside
Dada Nexus (DADA US) raised US$336m at US$16 per share, the mid-point of its IPO price range. The number of ADS sold was upsized by about 27%, to...
577 Views
I-Mab (天境生物) IPO Trading: Tiny Float and Undemanding Valuation
I-Mab (IMAB US) raised USD 104 million at USD 14.0 per ADS, above the mid-point of the IPO price range. I-Mab will start trading today. We have...
601 Views
ECM Weekly (12 Jan 2020) - Jiumaojiu, I-Mab, Phoenix Tree, Burger King India
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. We are...
609 Views
I-Mab (天境生物) IPO: Everest Deal a Valuation Booster
I-Mab launched the book building to raise up to USD 111 million via a listing on NASDAQ. In our previous notes, we covered the company’s key...
541 Views